vatalanib has been researched along with probenecid in 1 studies
Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (probenecid) | Trials (probenecid) | Recent Studies (post-2010) (probenecid) |
---|---|---|---|---|---|
276 | 42 | 98 | 3,664 | 292 | 375 |
Protein | Taxonomy | vatalanib (IC50) | probenecid (IC50) |
---|---|---|---|
Solute carrier family 22 member 8 | Mus musculus (house mouse) | 3.02 | |
Solute carrier family 22 member 6 | Homo sapiens (human) | 6.85 | |
Solute carrier family 22 member 8 | Homo sapiens (human) | 6.965 | |
Solute carrier family 22 member 8 | Rattus norvegicus (Norway rat) | 6.03 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for vatalanib and probenecid
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |